Option Care Health (OPCH) is back in focus after expanding its revolving credit facility by US$450 million and lifting its share repurchase authorization to US$1 billion, while reaffirming its 2026 guidance.
See our latest analysis for Option Care Health.
The recent 3.7% 1 day share price return and 1.7% 7 day share price return contrast with a 30 day share price return of 7.9% and a year to date share price return of 14.8%. The 1 year total shareholder return of 16.4% and 3 year total shareholder return of 12% highlight pressure on longer term holders despite a 5 year total shareholder return of 48.5%. This suggests momentum has been soft but may be stabilizing around the latest share price of US$27.47 as investors weigh the larger credit facility and expanded buyback.
If this kind of liquidity and buyback story has your attention, it could be worth scanning for other healthcare names with differentiated growth angles through 37 healthcare AI stocks
With Option Care Health trading at US$27.47 and sitting well below the average analyst price target of US$40.09, the key question is whether this gap reflects an undervalued home infusion leader or whether the market is already pricing in future growth.
Most Popular Narrative: 31.5% Undervalued
With Option Care Health’s fair value narrative sitting at $40.09 against a last close of $27.47, the current setup centers on how much long term earnings power the business can support under its at home infusion model.
Continued expansion of the company's national suite footprint and advanced practitioner model is improving nurse productivity and enabling the treatment of higher acuity, complex, and new therapeutic cohorts (including oncology and Alzheimer's), driving both margin improvements and new revenue streams.
Want to see what kind of revenue profile and margin lift needs to materialize for that valuation to hold up? The narrative leans on steady top line expansion, firmer profitability, and a richer earnings multiple tied to that cash flow outlook. The details behind those assumptions are where the story really gets interesting.
Result: Fair Value of $40.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story could still be knocked off course if reimbursement terms tighten or if the therapy mix continues tilting toward lower margin drugs and commoditized services.
Find out about the key risks to this Option Care Health narrative.
Another Angle On Value
There is a clear tension between the analyst fair value of $40.09 and Simply Wall St’s DCF output, which suggests Option Care Health’s future cash flows support a value of just $3.66 per share. That is a wide gap, so which set of assumptions feels closer to what you believe?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Option Care Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given the mix of optimism and concern running through this story, it makes sense to review the underlying data promptly and decide where you stand. A good starting point is the 4 key rewards and 2 important warning signs.
Looking for more investment ideas?
If Option Care Health has sharpened your focus, do not stop here. Use the screener to quickly line up fresh ideas that match your risk and return preferences.
- Spot potential value candidates early by scanning 58 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their underlying business strength.
- Build a portfolio that aims for resilience first by reviewing 67 resilient stocks with low risk scores to see which companies score well on balance sheet and risk metrics.
- Hunt for opportunities off the beaten path by checking the screener containing 25 high quality undiscovered gems before the wider market starts paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com